Current Issue : April - June Volume : 2018 Issue Number : 2 Articles : 6 Articles
Background. Breast cancer is the 5th leading cause of cancer death in Iranian women. This study analyzed 3010 women with breast\ncancer that had been referred to a cancer research center in Tehran between 1998 and 2014. Methods. In this retrospective study, we\nanalyzed 3010 breast cancer cases with 32 clinical and paraclinical attributes.We checked the data quality rigorously and removed\nany invalid values or records. The method was data mining (problem definition, data preparation, data exploration, modeling,\nevaluation, and deployment). However, only the descriptive analysesââ?¬â?¢ results of the variables are presented in this article. To our\nknowledge, this is themost comprehensive study on breast cancer status in Iran. Results. A typical Iranian breast cancer patient has\nbeen a 40ââ?¬â??50-year-oldmarriedwoman with two children,who has a high school diploma and no history of abortion, smoking, or\ndiabetes.Most patients were estrogen and progesterone receptor positive, human epidermal growth factor (HER) negative, and P53\nnegative. Most cases were detected in stage 2 with intermediate grade. Conclusion. This study revealed original findings which can\nbe used in national policymaking to find the best early detection method and improve the care quality and breast cancer prevention\nin Iran....
Background. Chemotherapy has become a standard of treatment in managing breast cancer. To achieve proper treatment for\nthe right patients, the predictive marker is needed. Ki-67 is a biomarker of proliferation for solid tumor. Studies mentioned\nassociation of Ki-67 expression with chemotherapy response. The study aims are to evaluate whether Ki-67 expression detected\nby immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT-PCR) may predict clinical response\nto neoadjuvant chemotherapy in breast cancer. Methods.This study utilized a longitudinal study. IHCand qRT-PCR methods were\nused for detection of Ki-67 expression. Chemotherapy response was calculated using RECIST. Data were analyzed with Chi-square\nand Wilcoxon�s test. Results. There were 48 subjects in this study. Analysis of Ki-67 expression with chemotherapy response has\na significant correlation with ...
Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease.Metronomic chemotherapy refers\nto the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged\ndrug-free breaks that leads to antitumor activity. In the present article, we review preclinical and clinical data of metronomic\nadministration of chemotherapy agents with or without biological agents in TNBC cell lines and patients, contextually reporting\ndata from the VICTOR-2 study in the subgroup of patients with TNBC, in order to stimulate new ideas for the design of clinical\ntrials in this subset of patients....
Background and Objectives. Most gastric cancer patients now undergo perioperative chemotherapy (POCT) based on the MAGIC\ntrial results. POCT consists of neoadjuvant chemotherapy (NACT) as well as postoperative adjuvant chemotherapy. This study\nassessed the applicability of perioperative chemotherapy and the impact of radical gastrectomy encompassing a detailed lymphnode\nresection on outcomes of gastric cancer. Methods. Medical and pathology records of all gastric carcinoma resections were\nreviewed from 2006 onwards. Pathological details, number of lymph-nodes resected, and proportion of involved nodes, reasons\nfor nonadministration of NACT, complications, recurrence, and survival data were analysed. Results. Only twenty-eight (37.8%)\nout of 74 patients underwent NACT and only nine completed POCT. NACT was declined due to comorbidities/patient refusal\n...
Background. There is little data regarding the effectiveness of palliative radiation with conventional fractionation for metastatic\nrenal cell carcinoma (RCC), which has been described as radioresistant. We conducted a retrospective analysis of patients with\nmetastatic bony disease from RCC treated with radiation therapy at our institution. Methods. Forty patients with histologically\nconfirmed RCC with a total of 53 treatment courses were included. Pain response after radiotherapy was recorded and freedom\nfrom progression was generated using posttreatment radiographs. Patient data was analyzed to assess influence on local control.\nResults. Patients had a median age of 63. Median follow-up was 9.3 months. The most common radiation dose was 30Gy in 10\nfractions. Pain control after radiotherapy was achieved in 73.6% of patients. Increasing age was associated with nonresponse at\nthe initial pain assessment post-RT (...
Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. It commonly occurs\nin hematological malignant patients particularly non-Hodgkin�s lymphoma and acute leukemia due to chemotherapy or\nspontaneously. It is characterized by a biochemical abnormality such as hyperuricemia, hyperkalemia, hyperphosphatemia, and\nhypocalcemia and its clinical outcome is directly related to these biochemical abnormalities. Prevention and treatment of tumor lysis\nsyndrome depend on immediate recognition of patients at risk. Therefore, identifying patients at risk and prophylactic measures\nare important to minimize the clinical consequences of tumor lysis syndrome. Patients with low risk should receive hydration\nand allopurinol. On the other hand patients with high risk should receive hydration and rasburicase in an inpatient setting. It is\nimportant to start therapy immediately, to correct all parameters before cancer treatment, to assess risk level of patients for TLS,\nand to select treatment options based on the risk level. In this review a comprehensive search of literatures was performed using\nMEDLINE/PubMed, Hinari, the Cochrane library, and Google Scholar to summarize diagnostic criteria, incidence, predicting\nfactors, prevention, and treatment options for tumor lysis syndrome in patients with hematological malignancies....
Loading....